Baseline characteristics of Achromobacter xylosoxidans-colonised and matched uncolonised patients with cystic fibrosis
| Characteristics | Control subjects (n=36) | Patients (n=36) | p-value |
| Female | 19 (52.8) | 19 (52.8) | 1.00 |
| Age years | 19.5 (17.0–27.0) | 23.5 (20.0–31.0) | <0.001 |
| BMI kg·m−2 | 20.6 (19.2–21.8) | 19.5 (17.7–21.0) | 0.12 |
| Homozygous F508del | 14 (41.2) | 14 (41.2) | 1.00 |
| Heterozygous F508del | 13 (36.1) | 17 (47.2) | 0.28 |
| Pancreatic insufficiency | 30 (83.3) | 30 (83.3) | 1.00 |
| Diabetes | 8 (22.2) | 11 (30.6) | 0.44 |
| Long-term azithromycin | 10 (27.8) | 14 (38.9) | 0.28 |
| Transplantation during follow-up | 0 (0.0) | 7 (19.4) | 0.011 |
| Lumacaftor+ivacaftor treatment | 7 (19.4) | 6 (16.6) | NA |
| Pseudomonas aeruginosa isolation | 27 (75.0) | 27 (75.0) | 0.56 |
| MSSA isolation | 21 (58.3) | 22 (61.1) | 0.82 |
| MRSA isolation | 5 (13.9) | 8 (22.2) | 0.37 |
| Burkholderia cepacia isolation | 4 (11.1) | 3 (8.3) | NA |
| Non-tuberculous mycobacteria | 2 (5.5) | 4 (11.1) | NA |
| Allergic bronchopulmonary aspergillosis | 11 (30.6) | 18 (50.0) | 0.071 |
| Intravenous antibiotherapy courses in the previous year n | 1.5 (0.0–5.0) | 2.0 (0.0–4.0) | 0.71 |
| Long-term (>6 months) maintenance antibiotherapy in the previous year n | 13 (40.6) | 19 (52.8) | 0.27 |
| Exacerbations in the previous year n | 2.0 (1.0–4.0) | 2.0 (1.0–3.5) | 0.77 |
| FEV1 at baseline % | 73.8 (67.2–80.4) | 55.2 (50.6–59.8) | 0.005 |
| FVC at baseline % | 88.1 (81.3–94.9) | 76.2 (71.5–81.0) | 0.22 |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant S. aureus; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity; NA: not analysed.